Is there an “Esteve ramipril indapamide” patent, and who holds it?
You can’t tell from the brand name alone. A product like “ramipril + indapamide” typically sits under one or more patents that may cover different things (the specific fixed-dose combination, the individual molecules, manufacturing methods, or later improvements). The company name “Esteve” usually refers to the marketing/manufacturing business, not necessarily the patent holder.
To identify the exact patent(s) for a specific Esteve ramipril/indapamide product, you need at least one of the following:
- the country/region (EU member state, UK, etc.)
- the product/marketing authorization number or the exact registered name
- the active-ingredient strengths in the fixed-dose combination
Once you have that, the relevant patents can be matched using those identifiers and local patent/market-exclusivity registers.
When would a ramipril–indapamide patent typically expire?
For combination antihypertensives, patent expiry usually depends on when the underlying invention was filed (and whether any regulatory extensions apply). In general terms, patents do not expire “per product brand”; they expire based on filing and legal term calculations for the specific patent. So the likely expiry date can vary a lot across:
- the particular patent family
- national extensions
- any paediatric or supplementary protection mechanisms in that jurisdiction
Without knowing which patent family (or which country) you mean, there is no single “Esteve ramipril indapamide patent expiry” date that can be stated accurately.
How to find the exact patent(s) for an Esteve ramipril/indapamide product in Europe
A practical way is to start from the marketing authorization in the country where you care about expiry, then look for:
- patent linkage or “SPC” (supplementary protection certificate) records tied to that marketing authorization
- listing of relevant patents in the local regulatory patent register/entry (where applicable)
- any SPC expiry dates (often the key dates for generic or biosimilar-style entry on EU pathways)
The exact register and available fields differ by country, but the method is the same: start from the authorization/product record, then connect to the named patents/SPCs.
Why your result might differ by country (EU vs UK vs others)
Even for the same medicine combination, exclusivity can differ by jurisdiction because:
- patent term adjustments and extensions are country-specific
- SPC coverage can be granted/denied differently
- approval and launch timelines affect when competitors can enter commercially
So you can see different “last day” dates in different markets even if the medicine is the same.
What happens when the patent/exclusivity ends?
Once the relevant patents/SPCs expire (and any other regulatory exclusivities also end), generic manufacturers can typically seek approval and then launch—subject to:
- whether any other still-active patents cover formulation or process elements
- local rules around patent challenges or competition actions
So “patent expiry” is often not the only gate; it’s the key one, but not always the only one.
What I need from you to give a precise patent answer
Send any one of these, and I can narrow it to the specific patents and expiry date(s):
- the country (e.g., Spain, UK, France, Germany, EU-wide)
- the exact product name and strength (e.g., ramipril X mg + indapamide Y mg)
- the marketing authorization number (or link) for the Esteve product
- whether you mean “patent” specifically or also “SPC/exclusivity”
Sources: None cited because the necessary patent/registry details weren’t provided and you requested an “Esteve ramipril indapamide patent” answer without enough jurisdiction/product information to verify a specific patent number or expiry date.